HC Wainwright restated their buy rating on shares of Viking Therapeutics (NASDAQ:VKTX) in a research report sent to investors on Tuesday, AnalystRatings.com reports. The brokerage currently has a $31.00 price objective on the biotechnology company’s stock.

Several other equities analysts have also recently weighed in on the stock. ValuEngine raised shares of Viking Therapeutics from a buy rating to a strong-buy rating in a research note on Friday, November 1st. Oppenheimer assumed coverage on shares of Viking Therapeutics in a research note on Tuesday, July 16th. They set an outperform rating and a $12.00 price target for the company. Citigroup assumed coverage on shares of Viking Therapeutics in a research note on Monday, July 15th. They set an outperform rating for the company. CIBC assumed coverage on shares of Viking Therapeutics in a research note on Tuesday, July 16th. They set an outperform rating and a $12.00 price target for the company. Finally, BidaskClub cut shares of Viking Therapeutics from a sell rating to a strong sell rating in a research note on Tuesday, August 6th. One analyst has rated the stock with a sell rating, eleven have assigned a buy rating and two have issued a strong buy rating to the stock. The company has an average rating of Buy and an average target price of $19.19.

NASDAQ VKTX opened at $7.86 on Tuesday. The business has a 50 day simple moving average of $6.76 and a 200 day simple moving average of $7.55. Viking Therapeutics has a 52-week low of $6.15 and a 52-week high of $13.78. The stock has a market cap of $564.69 million, a price-to-earnings ratio of -19.65 and a beta of 2.29.

Viking Therapeutics (NASDAQ:VKTX) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.05. Analysts anticipate that Viking Therapeutics will post -0.45 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Capital Investment Advisory Services LLC boosted its holdings in shares of Viking Therapeutics by 126.5% in the 2nd quarter. Capital Investment Advisory Services LLC now owns 3,850 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 2,150 shares during the last quarter. Quantamental Technologies LLC acquired a new stake in shares of Viking Therapeutics in the 2nd quarter valued at approximately $50,000. Tower Research Capital LLC TRC boosted its holdings in shares of Viking Therapeutics by 3,261.8% in the 3rd quarter. Tower Research Capital LLC TRC now owns 8,001 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 7,763 shares during the last quarter. Wedbush Securities Inc. acquired a new stake in shares of Viking Therapeutics in the 2nd quarter valued at approximately $97,000. Finally, Hayden Royal LLC acquired a new stake in shares of Viking Therapeutics in the 2nd quarter valued at approximately $111,000. 62.49% of the stock is owned by institutional investors.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol.

Featured Article: The role of implied volatility with call option volume

Analyst Recommendations for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.